2. Academic Validation
  3. Design of Ig-like binders targeting α-synuclein fibril for mitigating its pathological activities

Design of Ig-like binders targeting α-synuclein fibril for mitigating its pathological activities

  • Nat Commun. 2025 Aug 9;16(1):7368. doi: 10.1038/s41467-025-62755-1.
Shuyi Zeng 1 2,  Xingyu Xiong 3,  Houfang Long 4 5,  Qianhui Xu 4 5,  Yifan Yu 6,  Bo Sun 3,  Cong Liu 4 7 8 9,  Zhizhi Wang 3,  Wenqing Xu 3,  Shengnan Zhang 4 7,  Dan Li 10 11
Affiliations

Affiliations

  • 1 Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.
  • 2 Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, China.
  • 3 School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
  • 4 Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
  • 5 University of the Chinese Academy of Sciences, Beijing, China.
  • 6 Shanghai Starriver Bilingual School, Shanghai, China.
  • 7 State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
  • 8 Shanghai Academy of Natural Sciences (SANS), Fudan University, Shanghai, China.
  • 9 Shanghai Key Laboratory of Aging Studies, Shanghai, China.
  • 10 Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China. lidan2017@sjtu.edu.cn.
  • 11 Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, China. lidan2017@sjtu.edu.cn.
PMID: 40783395 DOI: 10.1038/s41467-025-62755-1
Abstract

Parkinson's disease (PD) is characterized by the accumulation and spread of pathological α-synuclein (α-syn) fibrils, which contribute to neuroinflammation and neurodegeneration. Here we show that two immunoglobulin-like (Ig-like) domains derived from α-syn receptors, the D1 domain of lymphocyte-activation gene 3 (L3D1) and the V domain of advanced glycation end-products (vRAGE), effectively block cell surface binding of α-syn fibrils, suppress fibrils-induced neuronal α-syn aggregation, and reduce inflammatory responses in microglia. Building on this, we identified two additional Ig-like Binders, the D1 domain of cluster of differentiation 4 (CD4 D1) and the D1 domain of chimeric antigen receptor (CAR D1), that target the C-terminal region of α-syn fibrils and mitigate fibrils-induced pathological activities. A structure-guided mutant, CAR D1_Mut, exhibits enhanced binding affinity and functional efficacy. These findings highlight the potential of Ig-like Binders as molecular tools to interfere with pathological α-syn interactions.

Figures
Products